Skip to main content
Erschienen in: Reactions Weekly 1/2012

01.05.2012 | Case report

Natalizumab

Hypersensitivity, with subsequent desensitisation: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Excerpt

An event is serious (FDA MedWatch definition) when the patient outcome is:
  • death
  • life-threatening
  • hospitalisation
  • disability
  • congenital anomaly
  • requires intervention to prevent permanent impairment or damage
Literatur
1.
Zurück zum Zitat Bignardi D, Ribizzi G, Voltolini S, Serrati C, Troise C.Successful desensitization to natalizumab in a skin test - Positive patient: A case report. Allergie et Immunologie 44: 26-29, No. 1, Feb 2012 - Italy Bignardi D, Ribizzi G, Voltolini S, Serrati C, Troise C.Successful desensitization to natalizumab in a skin test - Positive patient: A case report. Allergie et Immunologie 44: 26-29, No. 1, Feb 2012 - Italy
Metadaten
Titel
Natalizumab
Hypersensitivity, with subsequent desensitisation: case report
Publikationsdatum
01.05.2012
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2012
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.2165/00128415-201214020-00125

Weitere Artikel der Ausgabe 1/2012

Reactions Weekly 1/2012 Zur Ausgabe

Case report

BCG vaccine

Case report

Dronedarone

Case report

Lamotrigine